临床试验/NCT01299688

NCT01299688已完成不适用

HER2 Circulating Tumor Cells in Gastric Cancer

Samsung Medical Center1 个研究点分布在 1 个国家目标入组 135 人开始时间: 2010年3月最近更新: 2018年1月17日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: Samsung Medical Center
入组人数: 135
试验地点: 1
主要终点: To survey the frequency of HER2(+) CTC in gastric cancer

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer.

详细描述

We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be collected from metastatic gastric cancer patients.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Patients older than 18 years ② Patients with localized, histologically confirmed gastric cancer ③ Informed consent form

排除标准

•No informed consent form

结局指标

主要结局

To survey the frequency of HER2(+) CTC in gastric cancer

时间窗: 24month

次要结局

未报告次要终点

研究者

发起方

Samsung Medical Center

申办方类型

Other

责任方

Principal Investigator

主要研究者

Won Ki Kang

Professor

Samsung Medical Center

研究点 (1)

Loading locations...

相似试验

Unknown

不适用

The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using ImmunohistochemistryGastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue Blocks

NCT02843412Shanghai Zhongshan Hospital2,000

Unknown

不适用

Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin BlocksHER-2Gastric Cancer

NCT02852096Shanghai Zhongshan Hospital600

已完成

1 期

A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901HER2+ Cancer

NCT01526473H. Kim Lyerly22

Unknown

不适用

HER2 Positive CTC in Advanced Gastric CancerHER2 Positive Advanced Gastric Cancer

NCT01847794Peking University50

招募中

1 期

Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201Patients diagnosed with advanced or metastatic cancer treated with Trastuzumab Deruxtecan in the context of a clinical trial/expanded access/ compassionate use or standard treatment, irrespective of histologic type.

CTIS2023-508830-33-00Solti Group180